Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYCLONE 2: Abemaciclib + Abiraterone in mCRPC
NCT03706365Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Abemaciclib with Placebo (2 arms). Primary endpoint: Radiographic Progression Free Survival up to 60 Months. Started Nov 2018; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03706365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03706365.